In KRAS mutant lung cancer cells, oncogenic KRAS was proven to upregulate PD-L1 through an increase in PD-L1 mRNA stability mediated by the AU-rich element-binding protein tristetraprolin (TTP) [1]. Here, KRAS is linked to lung carcinoma.